Used in research settings as a selective inhibitor of the BRCA1-BARD1 interaction, B02 is instrumental in studying DNA repair mechanisms, particularly homologous recombination. It is widely applied in cancer research to sensitize BRCA-deficient cells to DNA-damaging agents, helping evaluate synthetic lethality approaches. B02 also supports studies on PARP inhibitor resistance by modulating BRCA1 function. Due to its ability to disrupt BRCA1-dependent ubiquitination, it serves as a tool compound in probing tumor suppressor pathways and developing targeted therapies for breast and ovarian cancers.